Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up.
De Rossi N, Scarpazza C, Filippini C, Cordioli C, Rasia S, Mancinelli CR, Rizzoni D, Romanelli G, Cossi S, Vettoretto N, Bove S, Manfredini S, Beindorf EA, Mosca C, Scipione V, Flamminio G, Albini EA, Giansiracusa P, Capra R; Montichiari COVID-19 Study Group. De Rossi N, et al. Among authors: mancinelli cr. EClinicalMedicine. 2020 Aug;25:100459. doi: 10.1016/j.eclinm.2020.100459. Epub 2020 Jul 17. EClinicalMedicine. 2020. PMID: 32838235 Free PMC article.
Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].
Scarpazza C, Prosperini L, Mancinelli CR, De Rossi N, Lugaresi A, Capobianco M, Moiola L, Naldi P, Imberti L, Gerevini S, Capra R. Scarpazza C, et al. Among authors: mancinelli cr. J Neurol Sci. 2017 Sep 15;380:19. doi: 10.1016/j.jns.2017.06.037. Epub 2017 Jul 4. J Neurol Sci. 2017. PMID: 28870565 No abstract available.
Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, Farinazzo A, Capra R, Mancinelli C, De Rossi N, Bombardi R, Zuliani L, Zoccarato M, Tanel R, Bonora A, Turatti M, Calabrese M, Polo A, Pavone A, Grazian L, Sechi G, Sechi E, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A. Mariotto S, et al. J Neurol. 2017 Dec;264(12):2420-2430. doi: 10.1007/s00415-017-8635-4. Epub 2017 Oct 23. J Neurol. 2017. PMID: 29063242 Free PMC article.
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
Prosperini L, Mancinelli C, Haggiag S, Cordioli C, De Giglio L, De Rossi N, Galgani S, Rasia S, Ruggieri S, Tortorella C, Pozzilli C, Gasperini C. Prosperini L, et al. J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):271-277. doi: 10.1136/jnnp-2019-322348. Epub 2020 Jan 23. J Neurol Neurosurg Psychiatry. 2020. PMID: 31974130
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study.
Prosperini L, Mancinelli CR, Solaro CM, Nociti V, Haggiag S, Cordioli C, De Giglio L, De Rossi N, Galgani S, Rasia S, Ruggieri S, Tortorella C, Capra R, Mirabella M, Gasperini C. Prosperini L, et al. Among authors: mancinelli cr. Neurotherapeutics. 2020 Jul;17(3):994-1004. doi: 10.1007/s13311-020-00847-0. Neurotherapeutics. 2020. PMID: 32236822 Free PMC article. Clinical Trial.
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group. Sormani MP, et al. Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9. Ann Neurol. 2021. PMID: 33480077 Free PMC article.
40 results